.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually decided on Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 as well as measured another nine titles in the space as obese. The investment bank pointed out in a details that it remains to strongly believe “diabesity is set to end up being.